Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

Immunic, Inc. Announces That Oral…

Immunic, Inc. Added to NASDAQ Biotechnology Index

Immunic, Inc. Added to NASDAQ…

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Immunic, Inc. Announces 200 Patients…

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

EIB Provides Immunic With up…

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Immunic, Inc. Announces Dosing of…

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunic, Inc. Announces Closing of…

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

Immunic, Inc. Announces Pricing of…

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Immunic, Inc. Announces First Patients…

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

Immunic, Inc. Announces Pricing of…

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

Immunic, Inc. Receives First Regulatory…